Curing metastatic testicular cancer

Proceedings of the National Academy of Sciences of the United States of America
Lawrence H Einhorn

Abstract

Our initial studies with cisplatin + vinblastine + bleomycin began 27 years ago in 1974, changing the cure rate for disseminated disease from 5 to 60%. Subsequently, through random prospective clinical trials, we have modified the treatment regimen to reduce both the duration and dosages of the chemotherapy drugs. Cisplatin + etoposide was first used at Indiana University as salvage chemotherapy in 1978, representing the first time that a solid tumor had been cured with second-line chemotherapy. We next did a clinical trial comparing bleomycin + etoposide + cisplatin (BEP) to cisplatin + vinblastine + bleomycin. The BEP regimen was proven to have less toxicity and a higher cure rate and therefore, since 1984, has been standard chemotherapy. More recent studies have evaluated the use of lesser chemotherapy to maintain the same cure rate for patients with good-prognosis disease. Standard therapy for these patients is either three courses of BEP or four courses of EP, and over 90% of these patients will be cured of their disease. Patients who are not cured with their initial BEP chemotherapy are usually treated with salvage chemotherapy. Approximately 50% of these testicular cancer patients will subsequently be cured with salvage ...Continue Reading

References

Dec 1, 1976·Cancer Treatment Reviews·M L SamuelsD E Johnson
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsL H Einhorn
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R BirchF A Greco
Jun 4, 1987·The New England Journal of Medicine·S D WilliamsP J Loehrer
Jun 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F OzolsR C Young
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H EinhornF A Greco
Nov 15, 1980·Cancer·S D WilliamsR Fletcher
Sep 24, 1981·The New England Journal of Medicine·L H EinhornF A Greco
Sep 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B M FitzharrisT J McElwain
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BanielL H Einhorn
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B SaxmanL H Einhorn
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerL H Einhorn
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BhatiaL H Einhorn
May 9, 2001·The Journal of Urology·K N GanjooL H Einhorn
Nov 5, 1960·JAMA : the Journal of the American Medical Association·J R OLDFORD, M N STEWART

❮ Previous
Next ❯

Citations

Jul 6, 2006·Der Urologe. Ausg. A·S KregeH Rübben
Feb 22, 2011·European Journal of Clinical Pharmacology·Curt Peterson
Feb 22, 2005·Cancer Chemotherapy and Pharmacology·Melissa L FishelM Eileen Dolan
Sep 16, 2004·Springer Seminars in Immunopathology·Yago NietoElizabeth J Shpall
Aug 10, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lawrence H Einhorn, Mary J Brames
May 25, 2006·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Jan OldenburgAlv A Dahl
Jun 1, 2005·DNA Repair·Anetta Nowosielska, M G Marinus
May 17, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Viktor Brabec, Jana Kasparkova
Oct 1, 2013·Expert Reviews in Molecular Medicine·R KosterS de Jong
Jul 27, 2012·Journal of the American Chemical Society·Sheng-Xiong HuangBen Shen
Jan 10, 2009·The Journal of Antibiotics·Arnold L Demain, Sergio Sanchez
Jul 2, 2003·Nature Reviews. Cancer·John R W Masters, Beate Köberle
Feb 3, 2005·Nature Reviews. Cancer·Jingyang Chen, JoAnne Stubbe
Jul 13, 2007·Nature Reviews. Cancer·Lloyd Kelland
Jul 21, 2012·Metallomics : Integrated Biometal Science·Shaoyu WangJanice R Aldrich-Wright
Aug 13, 2013·Metallomics : Integrated Biometal Science·Olga ReifschneiderUwe Karst
Mar 15, 2013·Metallomics : Integrated Biometal Science·Gerrit HermannGunda Koellensperger
Mar 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Kristie D GoodwinMillie M Georgiadis
Dec 29, 2009·The Journal of Biological Chemistry·Mustapha AouidaDindial Ramotar
Feb 3, 2011·The Journal of Biological Chemistry·Navjotsingh PablaZheng Dong
Sep 4, 2010·Antioxidants & Redox Signaling·Jennifer N Earley, John J Turchi
Nov 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R H A VerhoevenUNKNOWN EUNICE Survival Working Group
Mar 25, 2006·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Thomas MuellerHans-Joachim Schmoll
Mar 10, 2012·Molecular Cancer·Joshua D TompkinsChengtao Her
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mette SprautenLois B Travis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.